- Home
- MRKR
MRKR
Marker Therapeutics Inc.
as 03-26-2025 3:38pm EST
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $13.50 | AVG Volume (30 days): | 254.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.13 - $5.99 | Next Earning Date: | 05-14-2025 |
| Revenue: | $5,395,849 | Revenue Growth: | 79.04% |
| Revenue Growth (this year): | 195.4% | Revenue Growth (next year): | -79.14% |
Latest Marker Therapeutics Inc. News
MRKR Breaking Stock News: Dive into MRKR Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
Argus Research
3 months ago
Daily – Vickers Top Buyers & Sellers for 12/27/2024
Argus Research
3 months ago
Daily – Vickers Top Buyers & Sellers for 12/26/2024
Argus Research
3 months ago
Daily – Vickers Top Buyers & Sellers for 12/24/2024
MT Newswires
3 months ago
Marker Therapeutics to Raise $16.1 Million in Private Placement
GlobeNewswire
3 months ago
Marker Therapeutics Announces $16.1 Million Private Placement
GlobeNewswire
3 months ago
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma
GlobeNewswire
3 months ago
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer
Compare MRKR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRKR Marker Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.